AI Terminal
Eckert & Ziegler Strahlen- und Medizintechnik AG
Regulatory Filings • Nov 28, 2024
130_rns_2024-11-28_a9c6eda2-ef54-4083-8756-85da632ec16f.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 27 November 2024 09:00
Eckert & Ziegler Achieves European Approval for Theralugand® – Lutetium-177 Chloride (n.c.a)
EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch
Eckert & Ziegler Achieves European Approval for Theralugand® – Lutetium-177 Chloride (n.c.a)
27.11.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 27 November 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand ® , by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand ® in routine clinical applications throughout the European Economic Area (EEA).
Theralugand ® provides high-purity Lutetium-177 produced in compliance with GMP standards with specifications designed for the labelling of therapeutic radiopharmaceuticals. The approval unlocks its potential to support innovative cancer therapies such as those targeting neuroendocrine tumors and metastatic prostate cancer. The previous, GMP-certified Lutetium-177 was limited to investigational use in clinical studies.
Eckert & Ziegler collaborates with pharmaceutical companies worldwide to develop and manufacture Lutetium-177-based radiopharmaceuticals, furthering the reach of targeted radiotherapies for the global market. Through these partnerships, Eckert & Ziegler plays a vital role in providing innovative cancer treatments.
“We are excited to achieve the EC approval for Theralugand ® , a critical step in making innovative treatment options widely available for clinical applications across Europe,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This accomplishment reflects our dedication to the production and distribution of reliable therapeutic radiopharmaceuticals.”
Eckert & Ziegler is gearing up to meet the rising global demand for Lutetium-177 by actively expanding production capacities, ensuring a stable supply of this critical therapeutic radioisotope.
About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
**Contributing to saving lives.
Contact**
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
[email protected] / [email protected]
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
27.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Eckert & Ziegler SE |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2036955 |
| End of News | EQS News Service |